Skip to main content

Table 1 Baseline characteristics of participants in first 4 weeks

From: Memantine augmentation of sertraline in the treatment of symptoms and executive function among patients with obsessive-compulsive disorder: A double-blind placebo-controlled, randomized clinical trial

  Treatment Group
memantine+sertraline (= 35) placebo+sertraline (n = 30) P value
Mean±SD Count (%) Mean±SD Count (%)
Age (years) 35.03±11.35   334.83±10.30   
Gender Female   27
(77.1%)
  17
(56.7%)
0.07
Male   8
(22.9%)
  13
(43.3%)
Education Illiterate   0
(0.0%)
  1
(3.3%)
0.30
Primary   1
(2.9%)
  2
(6.7%)
Secondary   9
(25.7%)
  5
(16.7%)
High school diploma   9
(25.7%)
  13
(43.3%)
University Education   16 (45.7%)   9
(30.0%)
Marital status Single   18 (51.4%)   11 (36.7%) 0.08
Married   14 (40.0%)   17
(56.7%)
Divorced   0
(0.0%)
  2
(6.7%)
Separated   3
(8.6%)
  0
(0.0%)
Employment Employed   18
(51.4%)
  18 (60.0%) 0.71
Unemployed   7 (20.0%)   4
(13.3%)
Housewife   10
(28.6%)
  8
(26.7%)
Previous treatment Yes   4
(11.4%)
  2
(6.7%)
0.50
No   31
(88.6%)
  28 (93.3%)
Y-BOCS score (week 0) Total 27.88±5.65   30.11±5.79   0.12
Obsession 15.07±2.57   15.53±2.50   0.46
Compulsion 12.70±4.30   14.57±3.81   0.07
WCST score (week 0) Error 22.89±9.85   22.09±10.63   0.80
Categories 3.36±1.77   3.90±1.86   0.35
Perseveration 6.15±5.54   7.88±9.02   0.47
  1. SD standard deviation, Y-BOCS Yale-Brown Obsessive-Compulsive Scale